The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis by Holt, B. (Bronno) van der et al.
CLINICAL TRIALS AND OBSERVATIONS
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and
cytarabine in the treatment of elderly patients with previously untreated acute
myeloid leukemia (AML), in relation to MDR1 status at diagnosis
Bronno van der Holt, Bob Lo¨wenberg, Alan K. Burnett, Wolfgang U. Knauf, John Shepherd, Pier Paolo Piccaluga, Gert J. Ossenkoppele,
Gregor E. G. Verhoef, Augustin Ferrant, Michael Crump, Dominik Selleslag, Matthias Theobald, Martin F. Fey, Edo Vellenga,
Margaret Dugan, and Pieter Sonneveld, on behalf of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and
the United Kingdom Medical Research Council (MRC)
To determine whether MDR1 reversal by
the addition of the P-glycoprotein (P-gp)
inhibitor PSC-833 to standard induction
chemotherapy would improve event-free
survival (EFS), 419 untreated patients with
acute myeloid leukemia (AML) aged 60
years and older were randomized to re-
ceive 2 induction cycles of daunorubicin
and cytarabine with or without PSC-833.
Patients in complete remission were then
given 1 consolidation cycle without PSC-
833. Neither complete response (CR) rate
(54% versus 48%; P  .22), 5-year EFS
(7% versus 8%; P  .53), disease-free sur-
vival (DFS; 13% versus 17%; P  .06) nor
overall survival (OS; 10% in both arms;
P  .52) were significantly improved in
the PSC-833 arm. An integrated P-gp score
(IPS) was determined based on P-gp func-
tion and P-gp expression in AML cells
obtained prior to treatment. A higher IPS
was associated with a significantly lower
CR rate and worse EFS and OS. There
was no significant interaction between
IPS and treatment arm with respect to CR
rate and survival, indicating also a lack of
benefit of PSC-833 in P-gp–positive pa-
tients. The role of strategies aimed at
inhibitory P-gp and other drug-resistance
mechanisms continues to be defined in
the treatment of patients with AML. (Blood.
2005;106:2646-2654)
© 2005 by The American Society of Hematology
Introduction
The overall outcome of treatment of patients of older age with
acute myeloid leukemia (AML) has remained highly unsatisfac-
tory. In patients older than 60 years, complete response (CR) rates
are 45% to 60% only, while median disease-free survival (DFS)
values have been estimated at less than 12 months and the 4- to
5-year overall survival (OS) rates are approximately 10%.1-5
A potentially important biologic factor that may account for
chemotherapy resistance of AML in patients of higher age is the
high incidence of the intrinsic multidrug resistance (MDR) pheno-
type of leukemic blast cells.6 The MDR phenotype results from
expression of the MDR1 gene7,8 and its 170-kDa protein product,
P-glycoprotein (P-gp),9 also designated as adenosine triphosphate
(ATP)–binding cassette (ABC) transporter B1 (ABCB1).10 P-gp is
a transmembrane protein that acts as an energy-dependent drug
efflux pump for chemotherapeutic drugs such as the anthracyclines
and epipodophyllotoxins, commonly used in AML therapy.
Increased P-gp expression and enhanced drug efflux have been
reported with increasing age: from 17% in patients under the age of
35, 27% at 35 to 50 years, and 39% in patients over 50 years11 to
71% in a group with median age 68 years (range, 56 to 88 years).6
In retrospective studies MDR1/P-gp expression was associated
with lower CR rates and decreased OS and DFS in AML.12-16 Also
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P-gp positivity of AML is associated with other adverse prognostic
factors such as CD34 expression, secondary leukemia, and unfavor-
able cytogenetics.6,13,14,17
Based on these studies a rationale was developed for MDR1
modulation as a therapeutic approach.18 A variety of noncytotoxic
agents, such as verapamil, quinine, and cyclosporin A (CsA),
inhibit the P-gp transporter through competition with other sub-
strates for the binding sites of P-gp. These agents block P-gp–
mediated efflux of drugs from the intracellular compartment and
increase the intracellular accumulation of MDR-related drugs in
MDR-positive cells.19,20 Many of these P-gp reversal agents also
block the elimination of cytostatic drugs from the molecular pores
in the hepatobiliary canaliculi. By doing so they reduce hepatic
elimination of antileukemic drugs like anthracyclines, which results in a
prolonged half-life, an increase of the plasma area under the curve
(AUC), and potentially increased toxicity from these agents.21
Randomized phase 2 and phase 3 studies with first-generation
P-gp inhibitors in AML were mostly nonconclusive because of poor
therapeutic benefit or unexpected interactions with the pharmacoki-
netics of the cytostatic agent.22,23 Quinine and verapamil24 have a
cardiotoxic risk profile that prohibits adequate dosing.
The second-generation P-gp inhibitor PSC-833 (Valspodar,
Amdray; Novartis Pharma, Basel, Switzerland) is a cyclosporin
analog that is 7- to 20-fold more potent than CsA in increasing
daunorubicin (DNR) retention in MDR cells, while lacking the
immunosuppression and nephrotoxicity. The dose-limiting toxicity
is cerebellar ataxia, which, however, is transient and fully revers-
ible.25-27 Phase 1 and phase 2 studies suggest that substantial
inhibition of P-gp can be achieved in vivo at clinically tolerable
doses of both PSC-833 and DNR.28,29
Here we report the results of an international, multicenter,
open-label, randomized phase 3 trial of PSC-833 plus standard
chemotherapy in 419 previously untreated elderly patients with
AML, performed under the auspices of the Dutch-Belgian Hemato-
Oncology Cooperative Group (HOVON) and the United Kingdom
Medical Research Council (UK MRC). Two remission induction
regimens of DNR/cytarabine (Ara-C) and DNR/Ara-C/PSC-833
were compared for their effect on CR rate, event-free survival
(EFS), DFS, and OS. The effect of PSC-833 plus chemotherapy on
these outcome parameters in relation to the P-gp status at diagnosis
was also investigated.
Patients, materials, and methods
Patients
Patients 60 years or older with previously untreated primary or secondary
AML (M0 to M2 and M4 to M7, French-American-British [FAB] classifica-
tion adapted from Cheson et al30) and World Health Organization (WHO)
performance status 2 or below were eligible for this study. Patients with
secondary AML progressing from antecedent myelodysplastic syndrome
(MDS) were eligible if they had not been given chemotherapy previously.
Antecedent MDS was defined by a duration of at least 4 months. Patients
with promyelocytic leukemia (M3), blast crisis of chronic myeloid leuke-
mia, previous polycythemia rubra vera, or primary myelofibrosis were not
eligible. Other exclusion criteria were cytopathologically confirmed central
nervous system (CNS) infiltration, neurosensory toxicity grade 2 or above,
neurocerebellar toxicity grade 1 or above (National Cancer Institute of
Canada [NCIC] Expanded Common Toxicity Criteria [CTC]), known
positivity for HIV, impaired hepatic or renal function (alanine aminotrans-
ferase [ALT] and/or aspartate aminotransferase [AST] 2.5 or more times the
institutional upper limit of normal [IULN], alkaline phosphatase [AP] 2.5 or
more times the IULN, serum total bilirubin 1.5 or more times the IULN, and
serum creatinine 1.5 or more times the IULN after adequate hydration),
those receiving treatment interacting with CsA, previous surgery within 2
weeks or investigational therapy or radiotherapy within 4 weeks of study
entry, other primary malignancy except basal cell carcinoma of the skin or
stage 1 cervical carcinoma within the last 5 years, concurrent severe and/or
uncontrolled medical condition, psychological, intellectual, or sensory
dysfunction that was likely to impede ability to understand and comply with
study requirements, or severe cardiac or pulmonary disease.
The study was approved by the ethics committees of the participating
institutions and was conducted in accordance with the Declaration of
Helsinki. All patients gave written informed consent.
Registration and randomization procedures
Patients were randomly assigned to 1 of 2 induction chemotherapy
regimens without or with PSC-833, using a validated, voice-activated
telephone system, and stratified according to age (60 to 65, 66 to 70, and 71
or above) and secondary AML (no or yes).
Treatment
Induction chemotherapy consisted of 2 cycles of 45 mg/m2 DNR, 15
minutes of infusion on days 1 through 3, and 200 mg/m2 Ara-C every 24
hours, continuous infusion on days 1 through 7 (arm A); or a similar
regimen but with a lower dose of DNR (35 mg/m2) and with PSC-833, 2
mg/kg in a 2-hour loading dose followed by 10 mg/kg continuous
intravenous infusion every 24 hours for 72 hours days 1 through 3 (arm B).
The 22% dose reduction of DNR was based on the results of the pilot
study,28 which had established 35 mg/m2 DNR as the maximum tolerated
dose when administered concurrently with 10 mg/kg PSC-833 per day.
Cycle 2 was given to all patients who achieved a normocellular marrow
with less than 5% blasts, no Auer rods, and no evidence of extramedullary
involvement with full peripheral blood (PB) recovery (absolute neutrophil
count [ANC] above 1.0  109/L and platelets above 80  109/L) within 60
days of start of induction cycle 1. In patients with evidence of persistent
AML, the second cycle was administered independent of PB recovery.
Patients in both arms who attained a CR were to receive 1 consolidation
cycle without PSC-833 consisting of Ara-C 1 g/m2 6-hour infusion on days
1 to 4, mitoxantrone 6 mg/m2 by slow intravenous bolus on days 1 to 4, and
etoposide 80 mg/m2 1-hour infusion on days 1 to 4.
Definition of end points
In this analysis, CR was defined as a normocellular bone marrow (BM) with
less than 5% blasts, no Auer rods, and no evidence of extramedullary
involvement. Data on PB recovery within 60 days after start of a cycle were
not always available and were not considered as a criterion for CR. When
the BM blast cell count remained between 5% and 25% but was reduced by
at least 50% in comparison with the initial value, a patient was considered in
partial remission (PR). Patients who relapsed or died within 28 days after
CR were considered as not having achieved a CR. Patients who did not
enter CR following induction therapy were classified as induction death if
the patient died within 30 days after start of induction cycles 1 or 2 or as
having refractory disease otherwise.
Early death was defined as death during the first 7 days of the first
induction cycle.
EFS was determined from the date of randomization until no CR on
induction therapy, relapse after CR, or death in CR, whichever came first.
Patients who did not attain a CR were considered a failure at 1 day after
randomization. DFS was determined for all patients who achieved CR and
was calculated from the date of CR until relapse or death, whichever came
first. OS was measured from randomization until death from any cause.
Patients still alive at the date of last contact were censored.
Analysis of P-gp expression and function in AML samples by
flow cytometry
A BM aspirate of 3 to 10 mL was collected in a tube containing 0.5 mL
Hanks balanced salt solution (HBSS; Gibco, Paisley, United Kingdom)
with 625 U/mL sodium heparin. These samples were transported at 4°C or
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cryopreserved at –160°C and then transported to the central laboratory
in Rotterdam.
Mononuclear BM cells were collected from patient BM aspirates by
centrifugation over Lymphoprep (Nycomed, Oslo, Norway). They were
frozen in 10% dimethyl sulfoxide (DMSO) and 20% fetal calf serum (FCS)
and stored in liquid nitrogen. At the day of the analysis BM cells were
thawed, washed, and resuspended in Dulbecco modified Eagle medium
(DMEM; Gibco) supplemented with 10% FCS, gentamicin at a concentra-
tion of 4  106 cells per milliliter.
Measurement of the expression of P-gp. For measurement of the
expression of P-gp, cells were incubated (at room temperature) with
monoclonal anti–P-gp antibody MRK 1631 (Kamiya Biomedical, Tukwila,
WA) at a concentration of 10 g/mL or with UIC2 monoclonal antibody32
(mAb) (Immunotech, Marseille, France) at a concentration of 12.5 g/mL
or an isotype-matched control antibody monoclonal immunoglobulin G2a
(mIgG2a) (Sigma Chemical; St Louis, MO) at a concentration of 10 g/mL.
The concentrations of antibodies were based on our quality control studies33
and were also used in the pilot study.28 Cellbound antibodies were detected
by fluorescein isothiocyanate (FITC)–labeled rabbit anti–mouse immuno-
globulin antibodies (DAKO, Glostrup, Denmark).
To measure expression of P-gp in CD34 cells, cells were labeled with
phycoerythrin (PE)–labeled CD34 antibody or, as a control, PE-labeled mIgG1
antibody (Becton Dickinson, San Jose, CA). Cells were incubated with
0.1 M TO-PRO-3 (Molecular Probes, Eugene, OR) to exclude nonviable
cells. Fluorescence was measured using a FACScalibur (Becton Dickinson).
Results are given as the ratio of the mean of cell-associated fluorescence
of cells incubated with the anti–P-gp antibody divided by the mean of
cell-associated fluorescence of cells incubated with the control mIgG2a antibody.
Measurement of the function of P-gp. For measurement of the
function of P-gp,34,35 the fluorescent compound rhodamine 123 (Rho123;
Sigma) was used as a P-gp substrate. Cells were incubated for 1 hour at
37°C at 5% CO2 in the absence and presence of 2 M PSC-833. After this
incubation, 200 ng/mL Rho123 was added to the cells. A sample was taken
at t  0 minutes to correct for background fluorescence and at t 75
minutes to measure intracellular rhodamine accumulation.
To measure function of P-gp in CD34 cells, cells were labeled with
PE-cyanine 5 (Cy5)–labeled CD34 antibody or, as a control, PE-Cy5–
labeled mIgG1 antibody (Immunotech).
Cells were incubated with 0.1 M TO-PRO-3 to exclude nonviable
cells. Fluorescence was measured using a FACScalibur.
Results are given as the ratio of the mean intracellular Rho123
fluorescence of cells exposed to PSC-833 divided by the mean intracellular
Rho123 fluorescence of cells not exposed to PSC-833.
Interpretation. As controls in each analysis, the drug-sensitive human
myeloma cell line 8226 S and the drug-resistant variant 8226 D6 cells36
were used. Taking all experiments together, the mean efflux ratio (Rho123
PSC-833: Rho123) of the negative control cell line 8226 S was 0.92 0.06
(mean  SD; n  88) and of the positive control cell line 8226 D6 was
6.12  4.11.
Patient BM cells were considered positive for P-gp function if the efflux
ratio was more than 1.05. This ratio of P-gp efflux is given for the whole
population of blasts and also for the CD34 cells. Only patients with more
than 10% P-gp–positive cells in all experiments were considered positive.
The means of the MRK 16 expression ratio of the negative cell line
8226 S and of the positive cell line 8226 D6 were 1.28 0.26 and
27.17  6.37, respectively. The mean UIC2 expression ratios were
1.16  0.19 and 25.97  7.05, respectively. Patient BM cells were consid-
ered positive for the expression of P-gp if the expression ratio was more
than 1.65 for either MRK 16 or for UIC2. This ratio of the expression was
given for the whole population of blasts and also for the CD34 cells
together with the percentage of CD34 cells, which could be the leukemic
tumor cell population. Only patients with a subpopulation of more than 10%
of positive cells were considered positive. Some patients had P-gp
expression but no function. These patients were considered negative
because it is possible that these patients express a nonfunctional P-gp. Some
patients showed P-gp function but no expression. These patients were
considered positive because of the possible clinical relevance of this
phenomenon.
P-gp assessment. For patients with P-gp data available, an inte-
grated P-gp score (IPS) was based on the P-gp function or, if not
available, on the expression ratios.33 Patient BM samples were catego-
rized as negative (efflux ratio between 0 and 1.05), low-positive (more
than 1.05 to 1.40), intermediate-positive (more than 1.40 to 2.50), or
high-positive (more than 2.50). Similarly, cut points for expression
ratios were 1.65, 2.50, and 5.00. These cutoff values had been defined a
priori and were chosen based on the efflux ratios observed with the
doxorubicin-sensitive, P-gp–negative myeloma cell line RPMI 8226S
and its doxorubicin-resistant cell lines 8226DOX1, 8226DOX6, and
8226DOX40, which exhibit increasing levels of P-gp function, P-gp
expression, and cellular resistance (kindly provided by Dr W. S. Dalton,
H. Lee Moffitt Center and Research Institute, Tampa, FL).
Cytogenetic analysis
Cytogenetic analysis of BM samples obtained at diagnosis was performed
using standard cytogenetics techniques. All available cytogenetic reports
were reviewed by 2 expert cytogeneticists. Chromosomal abnormalities
were described according to the International System for Human Cytogenet-
ics Nomenclature (ISCN).37 Favorable risk was defined as the presence of
t(8;21), inv(16), or t(16;16). Unfavorable risk was defined by the presence
of monosomies or deletions of chromosomes 5 or 7, abnormalities of the
long arm of chromosome 3(q21;q26), t(6;9), abnormalities involving the
long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities
(defined as at least 3 unrelated cytogenetic clones). Patients who did not
meet the criteria for favorable or unfavorable risk were classified as being
intermediate risk.
Statistical considerations
The primary objective of the study was to compare EFS between the 2
treatment arms on an intention-to-treat basis—that is, patients were
analyzed according to assignment to treatment arm A (without PSC-833) or
B (with PSC-833). To detect with a power of 80% an increase in 2-year EFS
from 9.5% to 18% (2-sided significance level   .05) and assuming an
accrual of 18 months and a follow-up time of 12 months, 400 patients were
required and 331 events had to be observed.
Secondary end points were CR rate, DFS, and OS between the 2 treatment
arms, safety and tolerability of the 2 treatment regimens, and the association
between IPS and outcome and the interaction with additional PSC-833.
Patient characteristics between the 2 treatment arms were compared
using the Fisher exact test38 or the Pearson 2 test in case of discrete
variables or the Wilcoxon rank sum test39 in case of continuous variables.
The CR rate was compared between the 2 treatment arms using logistic
regression.40 The odds ratio (OR) was calculated with a 95% confidence
interval (CI).
EFS, DFS, and OS were estimated by the Kaplan-Meier method,41 and
95% CIs were constructed. Survival analysis was performed using Cox
regression42 to see whether there was a difference in survival between the 2
treatment arms. The hazard ratios (HRs) and corresponding 95% CIs were
determined for all 3 survival end points. Kaplan-Meier curves were
generated to illustrate differences between the 2 treatment arms and
compared using the log-rank test.43 Competing risk analysis was used to
calculate cumulative competing risks of treatment failure among patients
with a CR (either relapse after CR or death in first CR).
Safety was analyzed using descriptive statistics to summarize the
incidence of adverse events (AEs) and laboratory findings. Toxicity of the 2
regimens was assessed by laboratory evaluation, physical examination,
vital signs, and AE assessments. AEs were scored using the NCIC
Expanded CTC.
All reported P values are 2 sided, and a significance level  .05 was used.
Results
Patient characteristics
Between May 1997 and February 1999, 428 patients from 99
centers in 15 countries were randomized for study treatment. Eight
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patients were not eligible because of previous treatment (n 2),
impaired hepatic or renal function (n 2), or other (n 4). One
patient refused treatment after randomization and has been lost to
follow-up since. One patient aged 58 years was accidentally
randomized, but this was considered a minor protocol violation and
he has been included in the analysis. Of 419 remaining patients,
211 were randomized to arm A (control arm) and 208 were
randomized to arm B (induction therapy with PSC-833). Median
age was 67 years (range, 58 to 85 years). Patient baseline
characteristics were comparable between the 2 arms (Table 1).
Cytogenetics
Successful cytogenetic data were available for 293 (70%) of the
patients (Table 1). Five patients (2%) were classified as favorable
risk and 66 patients (23%) as unfavorable risk, while the remaining
222 patients (76%) were classified as intermediate risk, equally
distributed over the 2 treatment arms (P .70). A total of 158 of 222 of
intermediate-risk patients (71%) presented with a normal karyotype.
Response to chemotherapy
Of 419 patients, 285 patients (68%) received induction cycles only
and 128 patients (31%) received induction and consolidation
treatment. Six of 419 patients (1%) did not receive any protocol
treatment (Figure 1). Three of them received alternative induction
therapy, resulting in a CR in 2 patients: one patient withdrew
consent before cycle 1 and was treated with 6-mercaptopurine
instead, and one patient had an AE before the start of treatment and
was then treated with idarubicin instead of daunorubicin. Both
patients were considered as CR patients according to the intention
to treat. The overall CR rate was 51%. CR was achieved in 101 of
211 patients (48%) in the control arm as compared with 112 of 208
patients (54%) in the PSC-833 arm (P  .22). A total of 80 patients
in arm A and 87 patients in arm B achieved a CR after the first
induction cycle. Table 2 shows the CR rates by stratification factor.
Induction failures were classified as refractory disease or as
induction death in 79 (37%) and 31 (15%) patients, respectively, in
arm A, versus 63 (30%) and 33 (16%) patients, respectively, in arm
B. Early death rates were similar in both arms: 4 (2%) and 5 (2%)
patients, respectively.
Event-free survival, disease-free survival, and overall survival
The survival end points are based on follow-up data available as of
June 2004. The median follow-up of 56 patients still alive is 56
months; 35 of these patients were still in continuous first CR at last
contact, including 19 in the control arm and 16 in the PSC-833 arm.
Long-term EFS, DFS, and OS were similar for both treatment
groups (Table 3; Figure 2). Five-year EFS was 7% (95% CI,
4%-11%) for the PSC-833 group as compared with 8% (95% CI,
Figure 1. Flow diagram of 419 elderly patients with AML by treatment arm. Per
treatment arm, the number and percentage of patients who received a specific
induction or consolidation cycle are shown. R indicates randomization; MXT,
mitoxantrone; and ETO, etoposide.
*Six patients in arm B did not receive any protocol treatment.
†Two patients, one in each treatment arm, received only induction cycle 1 and one
consolidation cycle.
Table 1. Baseline characteristics of 419 elderly patients with AML by
treatment arm
Characteristic DNR/Ara-C
DNR/Ara-C
PSC-833
Total no. of patients 211 208
Median age, y (range) 67 (58-85) 67 (60-83)
58-65, no. (%) 77 (36) 77 (37)
66-70, no. (%) 71 (34) 69 (33)
71-85, no. (%) 63 (30) 62 (30)
Secondary AML
No, no. (%) 155 (73) 160 (77)
Yes, no. (%) 56 (27) 48 (23)
Sex
Male, no. (%) 117 (55) 132 (63)
Female, no. (%) 94 (45) 76 (37)
FAB classification
M0, no. (%) 14 (7) 17 (8)
M1, no. (%) 55 (26) 34 (16)
M2, no. (%) 70 (33) 74 (36)
M4, no. (%) 35 (17) 40 (19)
M5, no. (%) 14 (7) 19 (9)
M6, no. (%) 14 (7) 12 (6)
M7, no. (%) 4 (2) 1 (0)
Unclassified, no. (%) 5 (2) 11 (5)
WHO performance
0, no. (%) 41 (20) 45 (22)
1, no. (%) 110 (53) 103 (51)
2, no. (%) 54 (26) 49 (24)
3, no. (%) 1 (0) 4 (2)
No data, no.* 5 7
Median WBC count, 109/L (range) 7.0 (0.1-389) 11.3 (0.5-300)
P-gp assessment: IPS
Negative, no. (%) 37 (24) 45 (29)
Low-positive, no. (%) 50 (32) 40 (26)
Positive, no. (%) 43 (28) 42 (27)
High-positive, no. (%) 24 (16) 28 (18)
No data, no.* 57 53
Cytogenetic study at diagnosis
Not done, no. (%) 21 (12) 25 (14)
Done successfully,† no. (%) 146 (80) 147 (82)
Failure, no. (%) 15 (8) 8 (4)
No data, no.* 29 28
Cytogenetic risk classification†
Favorable, no. (%) 3 (2) 2 (1)
Intermediate, no. (%) 108 (74) 114 (78)
Unfavorable, no. (%) 35 (24) 31 (21)
WBC indicates white blood cell.
*Data not included when calculating percentages.
†Classification of cytogenetic abnormalities for 293 patients with successful
cytogenetics. Favorable risk was defined as the presence of t(8;21), inv(16), or
t(16;16). Unfavorable risk was defined by the presence of monosomies or deletions of
chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q26),
t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex
cytogenetic abnormalities (defined as at least 3 unrelated cytogenetic clones).
Patients who did not meet the criteria for favorable or unfavorable risk were classified
as being intermediate risk.
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5%-13%) for the control group (P  .53). Most patients who
reached a CR relapsed afterward. Ten versus 14 patients died in
CR, resulting in 5-year DFS of 17% (95% CI, 11%-26%) in the
PSC-833 arm and 13% (95% CI, 8%-20%) in the control arm;
P  .06. The 5-year OS was 10% (95% CI, 6%-15%) in both
treatment arms; P  .52.
P-gp assessment
Viable BM samples to assess P-gp status at diagnosis were
available in 309 of 419 patients (74%). Most samples were
transported at 4°C. Only samples from the United States, Canada,
and Australia were cryopreserved before transportation. Ulti-
mately, we had P-gp data of 35 patients with cryopreserved
samples, which is 11% of all patients with P-gp data available. P-gp
functional data were available in 282 patients, and P-gp expression
data were available in 293 patients. These data were highly
correlated. The Spearman rank correlation coefficient between the
efflux ratio and MRK 16 expression ratio was 0.64 (P  .001),
while between the MRK 16 and UIC2 expression ratio it was 0.81
(P  .001). Of the 265 patients with both P-gp functional and
expression data available, 11 patients had positive function and
negative expression, while in 30 function was negative and
expression positive. The 309 patients were classified as IPS
negative (27%), low-positive (29%), intermediate-positive (28%),
or high-positive (17%), with no difference between the 2 treatment
arms (P  .91; Table 1). An increased IPS was associated with a
lower CR rate; the CR rate decreased from 61% (95% CI,
50%-72%) and 54% (95% CI, 44%-65%) in the IPS-negative and
low-positive patients to 49% (95% CI, 38%-60%) and 40% (95%
CI, 27%-55%) in the IPS-positive and high-positive patients, respec-
tively (P .02, test for trend). A higher IPS was also associated with
significantly worse EFS and OS (Figure 3), and a trend for decreased
DFS was observed.
We also evaluated the mutual effect of PSC-833 and IPS on CR rate
and survival. A multivariate logistic regression analysis of CR rate was
performed with treatment arm, IPS, and a treatment arm by IPS
interaction term as covariates. EFS, DFS, and OS were also evaluated,
using multivariate Cox regression analyses. Similar results as in the
univariate analyses were obtained. No benefit of PSC-833 was seen,
while a higher IPS suggested a lower CR rate (OR 0.75; 95% CI,
0.54-1.03; P .07), a significantly lower EFS (HR 1.19; 95% CI,
1.01-1.40; P .04), and a trend for worse DFS (HR 1.22; 95% CI,
0.95-1.57; P .12) and OS (HR 1.12; 95% CI, 0.95-1.32; P .17).
Detailed results for CR rate, EFS, and OS are shown in Table 4.
However, none of the 4 analyses suggested an interaction between IPS
and treatment arm. Especially no greater benefit of PSC-833 was
apparent with increasing IPS. This was illustrated by a subgroup
analysis of the 227 patients with low-, intermediate-, or high-positive
IPS, who were expected to benefit most from PSC-833. Although the
CR rate was somewhat higher in the PSC-833 arm (55% versus 44%;
P .07), survival was not better. HRs for PSC-833 were 1.02 (95% CI,
0.78-1.33; P .91) for EFS, 1.34 (95% CI, 0.90-2.01; P .15) for
DFS, and 1.03 (95% CI, 0.78-1.35; P .84) for OS.
Adverse events
AEs affecting the central and peripheral nervous system and liver
and biliary disorders were more frequently reported in the patients
treated with PSC-833 and DNR than in those receiving DNR alone.
More AEs related to the nervous system were reported in patients
treated with PSC-833 and DNR, such as paresthesia (16.3% versus
1.9%), ataxia (13.9% versus 1.4%), or dizziness (26.2% versus
11.3%), whereas excess liver AEs among the PSC-833 treatment
group reflected more frequent reports of bilirubinemia (18.8%
versus 7.1%). The patterns of other reported AEs were similar for
the 2 treatment arms (Table 5).
Table 2. CR in AML in elderly patients by treatment arm and by stratification factors age and disease status
Characteristic DNR/Ara-C DNR/Ara-C PSC-833 Total
Total 101/211; 48% (41%-55%) 112/208; 54% (47%-61%) 213/419; 51% (46%-56%)
Age, y
58-65 43/77; 56% (44%-67%) 53/77; 69% (57%-79%) 96/154; 62% (54%-70%)
66-70 36/71; 51% (39%-63%) 33/69; 48% (36%-60%) 69/140; 49% (41%-58%)
71-85 22/63; 35% (23%-48%) 26/62; 42% (30%-55%) 48/125; 38% (30%-48%)
Secondary AML
No 79/155; 51% (43%-59%) 95/160; 59% (51%-67%) 174/315; 55% (50%-61%)
Yes 22/56; 39% (26%-53%) 17/48; 35% (22%-51%) 39/104; 38% (28%-48%)
Each cell contains the number of CR patients followed by the number of patients in the specific subgroup and the corresponding percentage, with its 95% CI.
Table 3. Effect of PSC-833 on outcome at 5 years
End point
DNR/Ara-C; N 211 DNR/Ara-C PSC-833; N 208
P RR* (95% CI)
No. of
events
Probability of
outcome at 5 y,
% (95% CI)
No. of
events
Probability of
outcome at 5 y,
% (95% CI)
CR rate 101 48 (41-55) 112 54 (47-61) .22 1.27 (0.87-1.87)
Event-free survival 192 8 (5-12) 192 7 (4-11) .53 1.07 (0.87-1.30)
Overall survival 181 10 (6-15) 182 10 (6-15) .52 1.07 (0.87-1.32)
Disease-free survival
after 1st CR 82 17 (11-26) 96 13 (8-20) .06 1.33 (0.99-1.78)
Relapse after 1st CR† 72 72 5 82 74 4 .10 1.31 (0.95-1.79)
Death in 1st CR† 10 10 3 14 13 3 .36 1.47 (0.65-3.32)
RR indicates relative risk of event.
*For CR rate, RR should be read as odds ratio (OR); OR and 95% CI are based on logistic regression. For all survival end points, RR should be read as hazard ratio (HR);
HR and 95% CI are based on Cox regression analysis.
†Relapse after first CR and death in first CR are competing risks; plus-minus values are the actuarial means standard error.
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Premature discontinuation of chemotherapy due to nonfatal AEs
was more frequent in the group treated with PSC-833 and DNR
than in the group treated with DNR alone (15.4% versus 9.5%). In
both groups, the most frequently reported reasons for premature
discontinuation were infections, while discontinuations due to
ataxia, cerebellar toxicity, or peripheral neuropathy were only
reported in patients treated with PSC-833 and DNR.
Deaths resulted from common complications of chemotherapy or
from progression of AML. PSC-833, which is known to increase
exposure to DNR by decreasing the clearance of the drug, did not lead to
increased incidence or severity of chemotherapy-related AEs.
Discussion
Expression of the MDR1 gene has been associated with lower CR
rates and worse OS and DFS in AML.
This randomized phase 3 study of the P-gp inhibitor PSC-833
aimed at overcoming classic MDR in patients with AML who were
60 years and older. It was designed to investigate whether the
response of AML would improve by adding PSC-833 to standard
induction treatment. This large study shows that PSC-833 does not
improve response rate or survival in patients with AML 60 years of
age and older. The overall CR rate was 51% and 5-year survival
was 10% in both treatment arms, which is comparable with other
published trials in this age group.1-5 To establish the independent
prognostic value of P-gp, an integrated P-gp score (IPS) of AML
blasts was prospectively determined at diagnosis. In this laboratory
analysis, 73% of evaluable patients were classified as P-gp positive
based on demonstrated P-gp reversal in vitro, which is in accor-
dance with previously published data in this patient group.6 We
confirmed that IPS is an independent adverse prognostic factor in
older patients with AML, because CR rate and EFS, DFS, and OS
decreased with increasing IPS. There was, however, no significant
interaction between IPS and PSC-833 with regard to CR rate and
survival end points.
Therapeutic P-gp reversal has been examined in several random-
ized phase 2 and phase 3 trials using first-generation P-gp
modulators such as quinine and CsA.
Quinine did not show an improvement in CR rate and OS in 2
consecutive trials by the French Groupe Ouest Est Leucemies
Aigues Myeloblastiques (GOELAM) mainly in patients with AML
aged 15 to 65 years,22,44 while toxicity was significantly in-
creased.22 In the subgroup of patients who were tested for P-gp, a
higher CR rate was observed in the 29 P-gp–positive patients in the
quinine arm (83% versus 48%; P  .01).44
The effect of CsA has been assessed in several trials in
refractory and relapsed AML. In the UK MRC Randomised Trial
for Patients with Refractory or Relapsed Acute Myeloid Leukaemia
in Adults (AML-R), OS and DFS did not differ between the CsA
and the standard arm, while a lower CR rate, due to increased
induction deaths and resistant disease, and worse OS were ob-
served in the subgroup of patients 60 years of age and older treated
with CsA.45 In the Southwest Oncology Group (SWOG) 9126 trial,
the incidence of refractory AML was lower in CsA-treated patients,
while OS and relapse-free survival (RFS) were better. The positive
effect of CsA was greatest in the subgroup of patients with
moderate or bright P-gp expression.46 A phase 2 trial by HOVON in
patients with relapsed/primary refractory AML failed to show improved
treatment outcome in the CsA-arm.23
PSC-833 is a second-generation P-gp reversal agent that lacks
immunosuppressive activity. Several phase 1 and phase 2 trials of
PSC-833 with natural product–based (re)induction chemotherapy
for AML were performed in refractory/relapse patients29,47-50 as
well as in untreated elderly patients.28,51,52 PSC-833 significantly
Figure 3. Kaplan-Meier survival curves of 309 elderly patients with AML by P-gp
assessment (IPS). (A) Event-free survival. (B) Overall survival.
Figure 2. Kaplan-Meier survival curves of 419 elderly patients with AML by
treatment arm. (A) Event-free survival. (B) Overall survival. No PSC indicates
patients in arm A.
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inhibits the hepatobiliary metabolism and excretion of cytotoxic
agents, which results in increased plasma exposure and slower
terminal elimination of anthracyclines. Therefore, the dosage of
agents that are substrates for P-gp (DNR, mitoxantrone, etoposide)
was reduced by 22% to 66% when applied concomitantly with
PSC-833 to accomplish equitoxicity with the control chemotherapy
regimen.28,48,51,53 In our trial the dosage of DNR was reduced by
22% in patients treated with PSC-833. While reduction of DNR
dose in PSC-833 patients may have contributed to an equitoxic
plasma exposure, it was expected that the inhibition of P-gp–
mediated drug efflux would compensate for that and would
overcome the P-gp–mediated drug efflux in leukemic cells. While
such an effect was indeed observed in the in vitro analysis of these
patient samples, PSC-833 did not confer a better therapeutic effect.
Other trials like the randomized phase 3 Cancer and Leukemia
Group B (CALGB) 9720 trial in elderly patients with untreated
AML54 and the Eastern Cooperative Oncology Group (ECOG)
2995 trial in relapsed/refractory AML and high-risk MDS55 also
failed to show a benefit of PSC-833. The first trial was prematurely
closed because of excessive early mortality in the PSC-833 arm,
while accrual to the second trial was discontinued early due to lack
of superiority in achieving CR in patients treated with PSC-833.
In these trials, there was no apparent difference in OS and DFS
between the 2 arms, but the power to detect moderate differences
was low due to the small patient numbers. The CALGB 19808 trial
in patients with AML younger than 60 years was halted in August
2003 because PSC-833 was no longer available,56 and results are
awaited. Our study in significantly greater numbers of patients,
with long follow-up and with elaborate P-gp analysis, failed to
reveal a benefit for the use of PSC-833, while the independent
prognostic value of P-gp at diagnosis was established.
Various reasons might be considered to explain why PSC-833
failed to overcome clinical refractory disease in older patients with
AML. First, dose reduction of DNR in the presence of PSC-833
from 45 mg/m2 to 35 mg/m2 in the experimental arm to achieve
equitoxicity may have inflicted reduced DNR exposure to AML
cells. This may have caused failure of PSC-833 to achieve durable
high intracellular levels of DNR in AML blasts. This issue may be
clarified by the trial conducted by the MRC group (the AML 14
Trial, which will shortly close) where an additional comparison
between a DNR dose of 35 mg/m2 and 50 mg/m2 is included.57
Second, the clinical benefit of PSC-833 may also have been
masked by the confounding contributing effect of Ara-C, which is
not a P-gp substrate. In fact, Ara-C is one of the most potent
antileukemic drugs available today.58 Third, several alternative
drug transport mechanisms may contribute to clinical resistance,
including intratumoral transmembrane transport proteins such as
members of the ABC superfamily of transport proteins including
MDR1, the multidrug resistance–related protein (MRP1/ABCC1),
and the breast cancer resistance protein (BCRP/ABCG2), or of the
lung resistance related protein (LRP), which extrude a variety of
cytotoxic drugs.21,59-61
The study presented here shows that addition of the P-gp
inhibition agent PSC-833 to standard induction chemotherapy does
not improve CR rate, EFS, DFS, and OS in patients aged 60 years
and older. In addition, MDR1 status at diagnosis remains an
independent adverse prognostic factor, indicating the need for other
strategies to overcome MDR1-mediated resistance.
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Table 4. Multivariate analyses of CR rate, event-free survival, and overall survival in 309 elderly patients with AML using treatment arm, IPS,
and treatment arm by IPS interaction as covariates
Variable
CR rate Event-free survival Overall survival
OR 95% CI P HR 95% CI P HR 95% CI P
PSC-833 arm 1.49 0.71-3.15 .29 1.16 0.78-1.71 .46 0.96 0.65-1.44 .86
IPS* 0.75 0.54-1.03 .07 1.19 1.01-1.40 .04 1.12 0.95-1.32 .17
PSC-833 arm IPS 1.05 0.68-1.63 .84 0.94 0.75-1.17 .57 1.06 0.85-1.33 .61
PSC-833 arm IPS indicates the interaction term between these 2 variables.
*IPS was coded as 0, negative; 1, low-positive; 2, intermediate-positive; 3, high-positive.
Table 5. Adverse events that have been reported in at least 20% of
the patients in at least one of the treatment arms
AE
DNR/Ara-C; N 211
DNR/Ara-C PSC-833;
N 202*
CTC 1-2, % CTC 3-4, % CTC 1-2, % CTC 3-4, %
Abdominal pain 21 1 31 3
Anorexia 16 4 17 3
Constipation 26 1 34 1
Coughing 23 1 25 2
Diarrhea 43 8 58 6
Dizziness 11 1 25 2
Dyspnea 18 10 22 11
Epistaxis 21 1 20 1
Febrile neutropenia/fever 51 38 51 33
Fluid overload 18 3 21 2
Headache 25 1 24 2
Herpes simplex 20 1 22 3
Hypertension 5 8 17 8
Hypokalemia 31 4 35 4
Hypotension 9 6 16 9
Infection 11 14 11 13
Injection site reaction 28 4 25 6
Mucositis n.o.s. 18 4 20 8
Nausea 49 5 47 9
Purpura 17 2 22 0
Rash 30 2 29 6
Rash erythematous 24 1 27 4
Rigors 27 1 27 2
Sepsis 12 24 20 19
Thrombocytopenia 4 19 3 17
Vomiting 43 0 48 2
Per treatment arm and per AE, the proportion of patients with a maximum grade
1-2 or 3-4 are shown. Proportions are rounded to the nearest integer. AEs were
graded according to the NCIC Expanded CTC.
n.o.s. indicates not otherwise specified.
*The 6 patients in the PSC-833 arm who did not receive any protocol treatment
have been excluded.
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